2:34 PM
 | 
May 03, 2019
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Keytruda monotherapy non-inferior to chemotherapy in first-line gastric cancer

Merck said April 25 that Keytruda pembrolizumab as monotherapy met the primary endpoint of non-inferiority to standard-of-care chemotherapy in improving overall survival (OS) in the Phase III KEYNOTE-062 trial as first-line treatment of gastric cancer. The pharma said the trial could serve as a potential confirmatory trial for the PD-1 inhibitor's accelerated approval.

In September 2017, FDA granted...

Read the full 270 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >